VIM and osteosarcoma: Decitabine exposure in osteosarcoma reduces the protein expression of the metastasis-associated markers VIMENTIN, SLUG, ZEB1, and MMP9, with a concurrent decrease in mRNA expression of the known stem cell markers SOX2, OCT4, and NANOG.